Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2014 Nov 8;15(11):516.
doi: 10.1186/s13059-014-0516-x.

A CRISPR design for next-generation antimicrobials

Chase L Beisel, Ahmed A Gomaa, Rodolphe Barrangou
Comment

A CRISPR design for next-generation antimicrobials

Chase L Beisel et al. Genome Biol. .

Abstract

Two recent publications have demonstrated how delivering CRISPR nucleases provides a promising solution to the growing problem of bacterial antibiotic resistance.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Delivering CRISPR-Cas9 for targeted killing and plasmid removal. Left: phages are engineered to encode the Cas9 nuclease, a trans-activating crRNA (tracrRNA) and an array of plasmid-targeting or genome-targeting CRISPR RNAs. The CRISPR RNAs are designed to target unique sequences in the bacterial chromosome or in harbored plasmids. Right: injection of the phage DNA into a mixed population of bacteria leads to removal (here depicted with broken lines) of targeted strains or plasmids without impacting the rest of the population. With further development, this strategy has the potential to treat multidrug-resistant infections without impacting beneficial microbes, to remove contaminating microbes from industrial fermentations and to provide further insights into microbial communities.
See this image and copyright information in PMC

Comment on

References

    1. Bikard D, Euler CW, Jiang W, Nussenzweig PM, Goldberg GW, Duportet X, Fischetti VA, Marraffini LA: Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials.Nat Biotechnol 2014, ᅟ:ᅟ. doi:10.1038/nbt.3043. - PMC - PubMed
    1. Citorik RJ, Mimee M, Lu TK: Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases.Nat Biotechnol 2014, ᅟ:ᅟ. doi:10.1038/nbt.3011. - PMC - PubMed
    1. Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S, Romero DA, Horvath P. CRISPR provides acquired resistance against viruses in prokaryotes. Science. 2007;315:1709–1712. doi: 10.1126/science.1138140. - DOI - PubMed
    1. Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell. 2014;157:1262–1278. doi: 10.1016/j.cell.2014.05.010. - DOI - PMC - PubMed
    1. Garneau JE, Dupuis M-È, Villion M, Romero DA, Barrangou R, Boyaval P, Fremaux C, Horvath P, Magadán AH, Moineau S. The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. Nature. 2010;468:67–71. doi: 10.1038/nature09523. - DOI - PubMed

Publication types

MeSH terms